Table IV.
Cox multivariate analysis of ZNF382 expression, promoter methylation and clinicopathological characteristics in pediatric AML.
| Variable | Odds ratio | EXP (B) 95% CI | P-value |
|---|---|---|---|
| Cytogenetics | |||
| Fav. vs. inter and unfav. | 4.569 | 2.216 (1.068–4.595) | 0.033 |
| MRD | |||
| <0.25 vs. ≥0.25% | 16.575 | 6.255 (2.588–15.119) | 0.000 |
| Leukocytes (/μl) | |||
| >10,000 vs. ≤10,000 | 0.083 | 1.088 (0.615–1.925) | 0.773 |
| FAB score | |||
| M7 vs. M1-M6 | 9.265 | 3.113 (1.498–6.469) | 0.002 |
| ZNF382 expression | |||
| Low vs. high | 0.045 | 0.939 (0.527–1.675) | 0.832 |
| ZNF382 methylation | |||
| Negative vs. positive | 1.326 | 0.690 (0.367–1.298) | 0.249 |
ZNF382, zinc finger protein 382; AML, acute myeloid leukemia; Fav., favorable; inter, intermediate; unfav., unfavorable; FAB, French-American-British classification; MRD, minimal residual disease.